Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

But we do have all these great treatments, and we're hoping that the overall survival of those patients will keep getting longer and longer, and maybe one day myeloma could be potentially cured. I ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

So I think this is one unmet need. Second, I think when we talk about CAR T, a lot of times we need to think what are the deal breakers for CAR T? So when a patient comes to my clinic, the first two ...

Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...